RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.
A global, double-blind, randomized, placebo-controlled, dose-finding, parallel-group trial was conducted to compare three oral doses of RPR100893 (1, 5, 20 mg), a substance-P antagonist, and placebo in 139 patients with migraine attacks with moderate or severe headache intensity. Headache intensity and improvement of headache after 2 h were not different in the four treatment groups. Therefore, it is concluded that this oral substance-P antagonist in the doses used here is not effective.
Diener
H-C
HC
Department of Neurology, University of Essen, Essen, Germany. h.diener@uni-essen.de
D000293:Adolescent; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D054833:Isoindoles; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D013373:Substance P / Q000037:antagonists & inhibitors* / Q000502:physiology
D007211:Indoles; D054833:Isoindoles; C089835:RPR 100893; D013373:Substance P